{"id":"NCT00250458","sponsor":"Organon and Co","briefTitle":"Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Elimination of Migraine-Associated Nausea in Migraine Patients Treated With Rizatriptan Orally Disintegrating Tablet (ODT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2006-10","completion":"2006-10","firstPosted":"2005-11-08","resultsPosted":"2010-06-23","lastUpdate":"2022-02-03"},"enrollment":346,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Comparator: Rizatriptan","otherNames":[]},{"type":"DRUG","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.","primaryOutcome":{"measure":"Participants With Elimination of Nausea at 2 Hours Postdose","timeFrame":"At 2 hours after treatment","effectByArm":[{"arm":"Rizatriptan 10 mg","deltaMin":130,"sd":null},{"arm":"Placebo","deltaMin":57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["18047500"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":200},"commonTop":["Dizziness","Somnolence","Vision blurred","Diarrhoea","Dry mouth"]}}